Drug Target Review

APRIL 7, 2025

Advancements in screening technologies for small-molecule drug discovery including cellular assays, computational screening, and biophysics-based methods enhanced by structural biology breakthroughs have improved screening hit rates and facilitated the identification of drug candidates for previously undruggable targets.

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

Drug Target Review

NOVEMBER 1, 2023

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Drug Target Review

OCTOBER 10, 2024

What are the risks of over-reliance on healthy donor material in early-stage research, and how can decision-makers ensure a balanced integration of diseased material to avoid potential gaps when transitioning to clinical trials? Healthy cells may also serve as a valuable control in experiments.

Therapies 52

Therapies Immune Response Clinical Trials Disease 52

Agency IQ

FEBRUARY 2, 2024

Prognostic biomarkers enable patient selection that would have a better clinical outcome irrespective of treatment. This enables patient selection, stratification and other adjustment in clinical trial design planning. biomarker negative) must also be supported by a sound rationale and clinical data.

Clinical Trials 40

Clinical Trials Trials Treatment Disease 40

Agency IQ

JULY 21, 2023

In general, FDA determines the “effectiveness” of a product based on its ability to demonstrate clinical benefit: to prolong life, improve function, and/or improve the way a patient feels. In parallel, FOCR developed a white paper that provided an overview of the potential regulatory applications for ctDNA in oncology.

FDA 40

FDA Clinical Trials Treatment Trials 40

Conversations in Drug Development Trends

JANUARY 6, 2025

Biomarkers are indispensable tools in clinical trials, providing critical insights that enhance the efficiency and precision of drug development. Our biomarker testing capabilities, offered across BioA and Clinical Pharmacology Unit (CPU) sites, provide a comprehensive and tailored approach to biomarker analysis.

Clinical Trials 52

Clinical Trials Trials Drug Development Therapies 52